Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study

• Published in: American journal of hematology Vol. 99; no. 10; pp. 1951 - 1958
• Main Authors: Zhao, Peng, An, Zhuo‐Yu, Fu, Hai‐Xia, Liu, Hui‐Xin, Feng, Cheng‐Jie, Huang, Qiu‐Sha, Wu, Jin, Wu, Ye‐Jun, Yang, Li‐Ping, Qu, Qing‐Yuan, Chen, Yu‐Xiu, Li, Meng‐Lin, Wang, Chen‐Cong, Chen, Qi, Zhu, Xiao‐Lu, He, Yun, Zhang, Yuan‐Yuan, Jiang, Qian, Jiang, Hao, Lu, Jin, Chang, Ying‐Jun, Zhao, Xiao‐Su, Zhao, Xiang‐Yu, Huang, Xiao‐Jun, Zhang, Xiao‐Hui
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.10.2024; Wiley Subscription Services, Inc
• Subjects: Adult; Adverse events; Aged; Autoimmune diseases; Azetidines - administration & dosage; Azetidines - adverse effects; Azetidines - therapeutic use; Corticosteroids; Drug Resistance; Female; Humans; Idiopathic thrombocytopenic purpura; Male; Middle Aged; Pilot Projects; Platelet Count; Platelets; Purines - administration & dosage; Purines - adverse effects; Purines - therapeutic use; Purpura, Thrombocytopenic, Idiopathic - drug therapy; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Quality of life; Recurrence; Steroids; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Thrombocytopenia; Treatment Outcome

Patients with steroid‐resistant or relapsed immune thrombocytopenia (ITP) suffer increased bleeding risk and impaired quality of life. Baricitinib, an oral Janus‐associated kinases (JAK) inhibitor, could alleviate both innate and adaptive immune disorders without inducing thrombocytopenia in several...